Skip to main content

Table 3 Additional treatment in CXCL13- high and CXCL13- low group

From: CXCL13 predicts disease activity in early rheumatoid arthritis and could be an indicator of the therapeutic `window of opportunity'

  DMARD + ADA DMARD
  CXCL13-high CXCL13-low CXCL13-high CXCL13-low
Additional treatment 6/27, 22.2% 4/10, 40% 9/23, 39,1% 6/16, 37,5%
  1. Number of patients in the CXCL13-high and -low group treated with additional DMARDs than MTX. If sulphasalazine, hydroxychloroquine or both has been added to the treatment during the 2-year follow-up patients will be considered to be receiving additional treatment. x/y represents the number of patients receiving additional treatment/number of patients in the group. ADA: adalimumab; CXCR13: C-X-C chemokine receptor type 13; DMARD: disease-modifying anti-rheumatic drug.